Hematology TimesBenefits of gemtuzumab ozogamicin outweigh risks, ODAC saysJuly 13, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Hematology TimesFDA grants priority review to sNDA for dasatinibJuly 12, 2017Leukemia, Myelodysplasia, TransplantationPediatricsPharmacyCML
Hematology TimesVaccine granted orphan designation for MDSJuly 11, 2017AnemiaPharmacyMyelodysplastic Syndrome
Hematology TimesEC approves therapy for relapsed/refractory BCP-ALLJuly 4, 2017Leukemia, Myelodysplasia, TransplantationPharmacyALL
Hematology TimesFDA unveils plan to eliminate orphan designation backlogJuly 1, 2017PharmacyRelated Issues
Hematology TimesBetrixaban receives FDA approval for VTE prophylaxis in adultsJune 26, 2017ThrombosisPharmacy
Hematology TimesNew SC rituximab formulation approved, reduces administration timeJune 24, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesFostamatinib under review by FDA for chronic ITPJune 21, 2017AnemiaThrombosisPharmacyBleeding Disorders
Hematology TimesBiosimilar rituximab approved in EuropeJune 20, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesCompany pauses enrollment on 2 trials of pembrolizumab in MMJune 14, 2017Multiple MyelomaPharmacy
